Search
Comprehensive DNA and RNA genomic profiling for myeloid malignancy research
The Oncomine Myeloid Assay GX v2 is a targeted next-generation sequencing (NGS) assay designed for rapid and sensitive detection of key relevant myeloid mutations. For use on the Ion Torrent Genexus Integrated Sequencer, the assay enables automated DNA and RNA variant detection with minimal hands-on time and can deliver a comprehensive myeloid mutational report in as little as 24 hours.
Oncomine Myeloid Assay GX v2 overview
The Oncomine Myeloid Assay GX v2 is a comprehensive targeted NGS panel for genomic profiling in myeloid malignancy research. The assay detects key DNA mutations and RNA fusion transcripts associated with disorders such as:
- Acute myeloid leukemia (AML)
- Myelodysplastic syndromes (MDS)
- Myeloproliferative neoplasms (MPNs)
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
Why choose Oncomine Myeloid Assay GX v2
The Oncomine Myeloid Assay GX v2 combines broad variant coverage, workflow automation, and rapid turnaround time to support efficient myeloid genomic profiling.
Key benefits include:
- Comprehensive DNA and RNA profiling in one assay, enabling simultaneous detection of multiple variant classes
- Rapid results in as little as 24 hours, depending on workflow configuration
- Automated sample-to-report workflow on the Genexus system and processes samples with just 20 minutes of hands-on time
- Sensitive detection of low-frequency variants, supporting reliable mutation identification
- Reliably detect a wide range of variants, including challenging-to-sequence targets like FLT3-ITD
Profile key myeloid mutations with one test
Simultaneously interrogate 45 DNA target genes and 34 fusion driver genes (RNA). This broad fusion panel allows you to sequence over 800 unique fusion transcripts. Gene content on the panel has been curated to cover relevant targets for all the major myeloid disorders—AML, MDS, MPN, CML, CMML, and JMML.
| Hotspot genes | Full genes |
Fusion drivers | Expression genes |
Expression controls |
| 28 | 17 | 34 | 5 | 5 |
Oncomine Myeloid GX v2 complete coverage of key genes
| Hotspot genes (28) | Full genes (17) | Fusion drivers (34) | Expression genes (5) | Expression controls (5) | |||||
| ANKRD26 | IDH1 | PPM1D | ASXL1 | RB1 | ABL1 | HMGA2 | NUP98 | BAALC | EIF2B1 |
| ABL1 | IDH2 | PTPN11 | BCOR | RUNX1 | ABL2 | JAK2 | NUP214 | MECOM | FBXW2 |
| BRAF | JAK2 | SMC1A | CALR | SH2B3 | BCL2 | KAT6A (MOZ) | PAX5 | MYC | PSMB2 |
| CBL | KIT | SMC3 | CEBPA | STAG2 | BRAF | KAT6B | PDGFRA | SMC1A | PUM1 |
| CSF3R | KRAS | SETBP1 | ETV6 | TET2 | CCND1 | KMT2A (includes PTD) | PDGFRB | WT1 | TRIM27 |
| DDX41 | MPL | SF3B1 | EZH2 | TP53 | CREBBP | MECOM | RARA | ||
| DNMT3A | MYD88 | SRSF2 | IKZF1 | ZRSR2 | EGFR | MET | RUNX1 | ||
| FLT3 (ITD, TKD) | NPM1 | U2AF1 | NF1 | ETV6 | MLLT10 | TCF3 | |||
| GATA2 | NRAS | WT1 | PHF6 | FGFR1 | MRTFA (MKL1) | TFE3 | |||
| HRAS | PRPF8 | FGFR2 | MYBL1 | ZNF384 | |||||
| FUS | MYH11 | ||||||||
| NTRK2 | |||||||||
| NTRK3 | |||||||||
Variant detection capabilities
The Oncomine Myeloid Assay GX v2 is designed to detect a broad range of genomic alterations relevant to myeloid malignancies.
DNA variant types:
- Single nucleotide variants (SNVs)
- Insertions and deletions (indels)
- Internal tandem duplications (ITDs)
- Partial tandem duplications (PTDs)
RNA variant types:
- Gene fusions and translocation transcripts
Workflow with the Ion Torrent Genexus System
The Oncomine Myeloid Assay GX v2 is optimized for the Ion Torrent Genexus System, enabling automated processing from sample to variant report. The integrated system minimizes manual steps and helps reduce workflow complexity, helping laboratories standardize myeloid genomic profiling.
Streamlined sample-to-report workflow
1
Sample input
- Whole blood
- Peripheral blood leukocytes (PBLs)
- Bone marrow
2
End-to-end Genexus System
- Automated nucleic acid extraction
- Integrated library preparation
- Sequencing, analysis & reporting
3
Final report
- Customizable report
- Biomarkers linked to relevant evidence from public data sources
Bioinformatics reporting
The Oncomine Myeloid Gx v2 Assay combines targeted next-generation sequencing (NGS) with advanced bioinformatics reporting capabilities to deliver structured, genomic insights for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN).
Key benefits:
- Automated end-to-end bioinformatics pipeline for alignment, quality control, variant calling and RNA fusion detection
- Integrated DNA and RNA reporting in a single workflow for comprehensive myeloid genomic profiling
- Structured, laboratory-ready reports with variant summaries, VAF, coverage metrics, and QC indicators
- Standardized and scalable reporting framework that reduces bioinformatics burden and improves reproducibility across runs
Experiences of Oncomine Myeloid Assay GX v2 users
Advancements in Rapid NGS for Myeloid and Lymphoid Malignancies: Insights from Robert Baker
Join us for an insightful webinar where Robert Baker will present the transformative impact of rapid next-generation sequencing (NGS) technologies in the field of hematological malignancies. Discover how his laboratory has significantly reduced turnaround times and improved genomic profiling accuracy, streamlining laboratory workflows by integration of the Ion Torrent Genexus System and the Oncomine Myeloid Assay GX v2, which allows for comprehensive profiling and rapid detection of key variants. Don't miss this opportunity to learn about the latest advancements in NGS and their real-world applications.
Ordering information
Oncomine Myeloid Assay GX v2 frequently asked questions
The assay detects DNA variants including SNVs, indels, ITDs, and PTDs, as well as RNA fusion transcripts associated with myeloid malignancies.
The assay is optimized for the Ion Torrent Genexus Integrated Sequencer.
Results can be generated in as little as approximately 24 hours, depending on laboratory configuration.
Validated nucleic acid inputs derived from whole blood or bone marrow samples.
No. The assay is for Research Use Only and not intended for use in diagnostic procedures.
Featured resources
Ready to speak to a Thermo Fisher Scientific representative?
We will be happy to answer your questions and provide a demo of our NGS solutions.
For Research Use Only. Not for use in diagnostic procedures.
CN: 60385